• 40-Hz Flicker and Retinal Amyloid Clearance

  2026-08-30

  A 2026 mouse study links 40-Hz light flicker to increased MHC-II expression, microglial activation, and amyloid-β clearance in the aging retina. Its minocycline-based inhibition experiment supports microglial activity as a necessary component of the response, while also highlighting important limits for translating induced amyloid models to human age-related macular degeneration.

• Naloxone hydrochloride: Research Workflows

  2026-08-29

  Build cleaner opioid receptor signaling experiments with a high-purity antagonist suited to receptor, neural stem cell, immune, and behavioral models. This guide translates naloxone hydrochloride into practical assay workflows while using a PDK4 inhibitor study as a framework for staged validation—not as evidence of a shared mechanism.

• Ciprofloxacin: 5 Reliable Assay Scenarios

  2026-08-28

  This scenario-driven guide explains how Ciprofloxacin, SKU A8399, can support antimicrobial resistance research while preventing misinterpretation of cell viability, proliferation, and cytotoxicity readouts. It covers mechanism, compatibility, controls, resistance-aware interpretation, and practical product-selection criteria using product specifications and recent epidemiological evidence.

• Acetylcysteine in 3D Tumor-Stroma Assays

  2026-08-28

  Learn how Acetylcysteine and N-acetyl-L-cysteine can be deployed as controlled redox perturbations in organoid–fibroblast models, rather than treated as generic antioxidants. This workflow connects oxidative stress pathway modulation with patient-specific chemoresistance assays and provides practical dosing, controls, and troubleshooting guidance.

• Staurosporine: Kinase Signaling Workflow Guide

  2026-08-27

  Build reproducible apoptosis and kinase-signaling assays with Staurosporine, while separating genuine pathway effects from cryopreservation and handling artifacts. This guide combines dose–time design, THP-1 assay preparation, VEGFR signaling applications, and practical troubleshooting for cancer research.

• Imipenem for Spatial Antimicrobial Research

  2026-08-27

  Imipenem can serve as more than a broad-spectrum antibacterial research reagent. This article examines how its PBP-directed activity and reported immune effects could be evaluated within spatially resolved implant and sepsis assays, while clearly separating established evidence from future platform applications.

• EZ Cap™ Human PTEN mRNA (ψUTP) Workflow

  2026-08-26

  Use EZ Cap™ Human PTEN mRNA (ψUTP) to model transient PTEN restoration, interrogate PI3K/Akt signaling pathway inhibition, and build delivery workflows for cancer research. Its Cap 1 structure, poly(A) tail, and pseudouridine modification provide a practical starting point for testing expression, pathway response, and resistance biology without constructing a new transcript.

• PTEN mRNA Nanoparticles Reverse Trastuzumab Resistance

  2026-08-26

  Dong and colleagues developed a tumor-microenvironment-responsive nanoparticle platform that systemically delivers PTEN mRNA to trastuzumab-resistant HER2-positive breast cancer models. By restoring PTEN expression and restraining persistently active PI3K/Akt signaling, the approach improved trastuzumab responsiveness and illustrates how delivery design is central to therapeutic in vitro transcribed mRNA research.

• Novel PDK4 Inhibitors for Metabolic Disease Research

  2026-08-25

  The reference study used anthraquinone-based structural modification to discover allosteric pyruvate dehydrogenase kinase 4 inhibitors, identifying compound 8c as a potent lead with activity in biochemical and mouse disease models. Its integrated medicinal chemistry, pharmacokinetic, docking, metabolic, metabolic-disease, allergy, and cancer experiments support PDK4 as a broad but still preclinical therapeutic target.

• Lapatinib (GW572016) Research Workflow

  2026-08-25

  Build receptor-defined kinase assays, cell proliferation studies, and invasion workflows around Lapatinib, a reversible EGFR and HER2 inhibitor. The approach also shows how phenotype-first experiments in HER2-low models can reveal treatment effects without overstating target engagement.

• Bafilomycin C1 in Translational Screening

  2026-08-24

  V-ATPase inhibition is more than an autophagy endpoint: it is a mechanistic stress test for lysosomal function, intracellular pH control, and phenotypic assay resilience. This thought-leadership article explains how Bafilomycin C1 can strengthen autophagy assays, apoptosis research, cancer biology studies, and high-content workflows, while showing how lessons from deep-learning cardiotoxicity screening can be translated carefully across domains.

• BRD4–RAC1 Co-targeting in Breast Cancer

  2026-08-24

  Ali et al. show that co-inhibiting BRD4 and RAC1 with JQ1 and NSC23766 suppresses growth, migration, stem-like phenotypes, and xenograft tumorigenesis across breast-cancer subtypes. The study connects these effects to disruption of the c-MYC–G9a–FTH1 axis and HDAC1/Ac-H3K9 signaling, offering a mechanistic framework for evaluating G9a-directed probes without equating them to the tested combination.

• AMG 9810: TRPV1 Antagonist for Mechanistic Assays

  2026-08-23

  AMG 9810 is a selective TRPV1 antagonist for separating receptor-driven calcium and neuropeptide responses from broader cellular stress signals. This article connects sensory-neuron assay design with the AMPK–SQSTM1 metabolic-stress framework while defining what the compound can—and cannot—prove experimentally.

• Intestinal Stretch, Obesity, and Weight-Loss Recovery

  2026-08-22

  The reference study identifies intestinal stretch as an acute regulator of food intake and glucose tolerance that can operate independently of classical GLP-1 signaling. It further shows that obesity weakens this mechanosensory response, whereas dietary weight loss and vertical sleeve gastrectomy restore associated neuronal activation and feeding suppression.

• Semaphorin Receptors Antagonize Wnt Signaling

  2026-08-21

  A 2024 bioRxiv preprint reports that Neuropilin and Plexin semaphorin receptors suppress Wnt signaling by promoting proteasome-dependent β-catenin destabilization, independently of primary cilia. The findings identify receptor-specific control points downstream of Dishevelled and suggest that GSK3β/CK1 dependence differs between Neuropilins and Plexins, with implications for interpreting pharmacological Wnt experiments.

7718 records 1/515 page Next 12345 下5页 Last page